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Abstract 
Kinetic constants of K M = 0.8 /zM, 3 /zM and 1.6 /xM, and kca t = 9 s -~, 7 s -~ or 9 s-~ were determined for histidine 
dephosphorylation by protein phosphatases 1, 2A and 2C respectively. IC50 values were determined for the inhibition of protein 
phosphatase 1 by inhibitor 1 (IC5o = 1 nM), inhibitor-2 (IC50 = 3 nM) and okadaic acid (IC50 ---- 30 nM) and for the inhibition of protein 
phosphatase 2A by okadaic acid (IC5o = 0.02 nM) and microcystin-LR (IC5o = 1 nM). Inhibitor-I (K i = 0.7 nM) and okadaic acid 
(K i = 32 nM) are noncompetitive with protein phosphatase 1. Some of the IC5o values were low enough to violate the assumptions ofthe 
usual inhibition equations and a more general approach to the analysis of the data was used. On the basis of these kinetic parameters and 
the presence of phosphohistidine, the major cellular protein serine/threonine phosphatases are likely to act as protein histidine 
phosphatases in the cell. 
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I. Introduction 
Protein phosphatases are key components of signal 
transduction and other regulatory events in eukaryotic ells 
[1-5]. In some circumstances, the role of protein phospha- 
tases in regulation has been clearly defined, such as in the 
regulation of glycogen metabolism by the cyclic AMP-de- 
pendent protein kinase [1]. In other circumstances, the 
critical nature of the role of protein phosphatases is shown 
by the effects of specific inhibitors, particularly okadaic 
acid acting as a tumour promoter [6] or microcystin acting 
as a potent oxin. In these cases, however, the nature of the 
protein substrates involved is still under intensive investi- 
gation. 
Histidine phosphorylation in eukaryotic proteins [7] was 
reported by Boyer and his colleagues in the 1960s [8,9]. 
The phosphate is linked to histidine through a phospho- 
ramidate (P-N) bond which is stable at alkaline pH but 
unstable at acidic pH [I0]. Although phosphohistidine as
an amino acid is relatively unstable at neutral pH (espe- 
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cially the 1-isomer), the phosphohistidine in histone H4 is 
relatively stable at pH 7.5, possibly due to the absence of 
the a-amino group which has been implicated in the 
instability of 1-phosphohistidine [10,11]. Phosphohistidine 
is completely degraded by the acid hydrolysis conditions 
used for phosphoamino acid analysis [10,12,13] and is thus 
not seen in most studies of protein phosphorylation. Histi- 
dine phosphorylation has been reported on histone H4 in 
proliferating rat tissues [14,15] and on a rat plasma mem- 
brane protein [16-19] whose expression is negatively cor- 
related with cell division. None of these reports address the 
question of how much phosphohistidine is present in cellu- 
lar proteins. There are several estimates of alkali-stable 
phosphate in eukaryotic proteins (reviewed in Ref. [7]) but 
this does not solely represent phosphohistidine. Current 
data from our laboratory (Pesis and Matthews, unpub- 
lished) indicate that 5% to 7% of the phosphate in nuclear 
proteins from the slime mould, Physarum polycephalum, 
is in phosphohistidine. This is approximately equivalent to 
the amount of phosphothreonine, much less than phospho- 
serine, but much higher than phosphotyrosine which is less 
than 1% of protein phosphate. 
Recently, two eukaryotic genes were discovered with 
deduced protein domains homologous to bacterial histidine 
kinase domains. One of these genes is involved in ethylene 
receptor action and may code for the receptor itself [20]; 
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the other is involved in regulation of protein degradation i  
budding yeast [21] and regulates the osmosensing MAP 
kinase cascade [22]. Two mitochondrial protein serine 
kinases homologous to the bacterial histidine kineses have 
been described [23,24]. Yeast cells (Saccharomyces cere- 
visiae) contain a specific protein histidine kinase [25] and 
protein histidine kinase activity has been found in several 
rat tissues [26], in the slime mold Physarum polycephalum 
[27], and in rat cell lines [28] (H.R.M., unpublished). 
In the bacterial two-component regulatory system, the 
histidine phosphate produced by the kinase domain is 
transferred to an aspartate residue in an effector protein 
[29]. In eukaryotes, the catalytic subunits of protein phos- 
phatases 1, 2A and 2C were shown to act on phosphohisti- 
dine in histone H4 but the data are largely qualitative [30]. 
Protein lysine phosphatases and protein histidine phospha- 
tases have been inferred from data with phosphorylated 
polylysine and polyhistidine [31 ] and phosphatases that act 
on free phosphohistidine or phospholysine have been re- 
ported [32]. Motojima and Goto [19] deduced the presence 
of a histidine phosphatase activity with several of the 
properties of protein phosphatase 2C in rat liver. We now 
report kinetic characterization f the protein histidine phos- 
phatase activities of protein phosphatases 1, 2A and 2C. 
2. Mater ials  and Methods  
2.1. Materials 
Histone H4 was purified from total calf thymus histone 
(Sigma Chemicals) by chromatography on a Biogel P-10 
gel filtration column (5 cm diameter × 1 m long) eluted 
with 10 mM HC1. Protein histidine kinase was purified 
from Saccharomyces cerevisiae and stored in liquid nitro- 
gen [13]. [32p]H4 was prepared by incubating histone H4 
with protein histidine kinase and [y-32p]ATP. After mild 
alkaline hydrolysis, [32p]H4 was recovered, unincorpo- 
rated ATP was removed [33], and the [32p]H4 was dial- 
ysed into phosphatase buffer A (50 mM Tris-C1 [pH 7.5], 
0.1 mM EGTA, 0.1% /3-mercaptoethanol) and frozen in 
aliquots. This substrate is stored in phosphatase buffer A at 
-20°C  or -70°C in aliquots and no degradation is found 
over the 4 weeks or so that it is used, although freezing 
and thawing must be avoided. If a sample of [3zp]H4 is 
allowed to stand at room temperature in phosphatase buffer 
A, phosphate is released at the rate of 5 to 6% per day so 
that under these conditions (pH 7.6) the phosphohistidine 
in histone H4 is reasonably stable. 
Protein phosphatases were gifts from Dr. Philip Cohen 
and his colleagues. The catalytic subunits of PP1 and 
PP2A (Dr. D. Schelling) [34] and inhibitor-1 (Dr. M. 
Hubbard) [35] were purified from rabbit skeletal muscle at 
the University of Dundee by the investigators indicated in 
parentheses. PP2C, also from rabbit skeletal muscle, was 
partially purified up to the Sephadex G-100 step [36] and 
provided by Miss J. Corton and Dr. D.G. Hardie, Univer- 
sity of Dundee. Inhibitor-2 expressed in E. coli was a gift 
to Dr. Philip Cohen from Dr. Anna De Paoli-Roach, 
University of Indiana, Indianapolis. Okadaic acid was a 
gift to Dr. Philip Cohen from Dr. Y. Tsukitani, Fujisawa 
Pharmaceutical Company, Tokyo, Japan. Microcystin-LR 
was provided by Dr. Carol MacKintosh, University of 
Dundee. The product of the CL100 gene was provided by 
Dr. D. Alessi and the phosphatase ncoded by phage A 
was provided by Dr. J. Dixon. 
Protein phosphatase assays were carried out [33] in a 
final volume of 30 /zl. Protein phosphatases ! and 2A 
were diluted with 1 mg bovine serum albumin/ml in 
phosphatase buffer A just prior to assay [34]. An aliquot, 
l0 /zl, of the diluted enzyme was mixed with 10 /zl of 
0.03% (w/v )  Brij-35 in phosphatase buffer A on ice. The 
reaction was initiated by adding 10 /xl of [32p]H4. After 
incubation at 30°C, the reaction was stopped by adding 
ice-cold 50 mM Na phosphate (pH 8.5), 0.1 mM EGTA to 
a final volume of 400 /zl. Released [32p]phosphate was 
separated by ultrafiltration [34]. The assay for PP2C con- 
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Fig. 1. Initial rate kinetics for protein histidine phosphatase activity of 
PP1, PP2A and PP2C. The left-hand panels how histidine phosphatase 
activity as a function of substrate concentration; the points are experimen- 
tal data; the lines are the best fit to the Michaelis-Menten quation 
(parameters in Table 1). The right-hand panels how the double reciprocal 
plots; the points are experimental data (the same as the left-hand panel 
data) and the lines are derived from the fit shown in the left-hand panel. 
The substrate is l-phosphohistidine at residue 75 in histone H4. 
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tained 10 mM Mg 2+. One Unit of phosphatase corre- 
sponds to the release of 1 /zmol of phosphate per minute. 
Although prolonged incubation or high enzyme concentra- 
tions will remove at least 90% of the [32p] from [32p]H4, 
the kinetic data reported here were all obtained with less 
than 20% of the [32 p] removed. 
Inhibitors were diluted in 0.03% (w/v)  Brij-35 in phos- 
phatase buffer A. Diluted protein phosphatase, 10 /xl, was 
preincubated with 10 /zl of diluted inhibitor for 2 min at 
30°C before starting the reaction [35]. 
2.2. Kinetic equations 
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Fig. 2. Mg 2+ requirement for protein histidine phosphatase activity of 
PP2C. PP2C was at 0.67 mU/ml and [histone H4] was 0.65 /xM. 
The Michaelis-Menten equation was used as: V = Vm, x " 
[S]/ (K M + IS]) and the best fit values of K M and Vma x
were determined by calculating V as a function of [S] for 
estimated values of K M and Vma x and determining the 
'error' between the calculated and experimental values. 
The sum of squared errors was minimized by varying K M 
and Vma x using the defauk non-linear minimization routine 
in the computer program, Microsoft Excel (version 4.0), 
and the values of K M and Vma x that gave the minimum 
sum of squared errors were taken as the best fit values. 
The same procedure was used to fit the equations for 
inhibition and to determine inhibition constants. The fol- 
lowing equations were used when inhibitor binding was 
small compared with its total concentration: competitive 
inhibition: 
[S]/Ks 
V=Vmax 
1 + [S]/Ks + [l]/Ki 
noncompetitive inhibition: 
[ S]/Ks 
v= Vmax 1 + [S]/Ks+ [l]/Ki+ [S].[I]/(Ks. Ki) 
uncompetitive inhibition: 
[S]/Ks 
V=Vm.x 1 + [S]/Ks + [S].[I]/(Ks. Ki) 
When this approximation was not valid, the following 
equations were derived from Henderson's analysis [37]:- 
Et -Kh- [ l ]+  ~(Kh-Et+[ I ] )  2 +4.Et.Kh 
V= Vo 
2. Et 
where Kh is given by the following expressions, pecific 
to the type of inhibition: noncompetitive inhibition 
Kh=Ki 
mixed noncompetitive inhibition 
[S] + Ks 
Kh= 
( Ks/Kis) + ([ S]/Kii) 
and competitive inhibition 
[S]+ Ks 
Kh=Ki - -  
Ks 
In these equations, Ks, Ki, Kis, Kii and Vma x are the 
kinetic constants, [S] and [I] are the substrate and inhibitor 
concentrations, respectively; V is the initial reaction veloc- 
ity; Vo is the reaction velocity in the absence of inhibitor; 
and Et is the total enzyme concentration. 
The latter approach was used for the fits shown as the 
solid lines in Fig. 3, Fig. 4A,B, Fig. 5 and Fig. 6. The best 
Table 1 
Comparison of the activity of protein phosphatases against phosphohistidine i  histone H4 and phosphoserine in phosphorylase a (PP1, PP2A) or myosin 
P-light chain (PP2C) 
Substrate: Phosphohistidine Phosphoserine 
KM Vmax Kcat Kcat/KM KM Vmax Kcat Kcat/KM 
Phosphatase: ~M U/mg s- i /xM- i s -  i /xM U/mg s-  i /xM- i s -  i 
PP1 0.8 16 9 11 18 a 40-50 b ~ 20 ~ 1 
PP2A 3 11 7 2 5 c 3 o 2 0.4 
PP2C 1.6 12 9 5 8 e 50 ~ 35 4 
Values for phosphorylase a: a value of 20 /zM was quoted in [70] and 18 p.M in [71]. 
b Given in [43] for the 33 kDa torm of PP1. 
c Values for phosphorylase a [7:2]. 
d Given in [43] for the 36 kDa catalytic subunit of PP2A. 
e Values for myosin P-light chain [73]; phosphorylase a is a very poor substrate for PP2C [42] 
224 Y. Kirn et al. / Biochimica et Biophysica Acta 1268 (1995) 221-228 
0 
E 
0 
>~ 
-4"-  ,m 
> 
°m 
g 
U 
(D 
o') 
O 
U ¢-- 
O_ 
O 
_C 
ft.. 
I O0 
8O 
60 
40 
20 
8O 
60 
40 
20 
I 
O.O01 
a- ' -~  i I-1 
, 
i . . .  j 
b I I-2 
" .  I 
'1. 
t m. 
J °° 
I • •° 
I "m 
I 
i I 
0.I 110 
[Inhibitor], nM 
Fig. 3. Inhibition of protein histidine phosphatase activity of PP1 by 
inhibitor-1 and inhibitor-2. Inhibitor concentration is shown on a logarith- 
mic scale. The vertical broken line is at 1 nM okadaic acid and the 
horizontal broken lines are at 50% inhibition. The upper panel shows data 
for inhibitor-1 and the lower panel for inhibitor-2. The inhibitor-1 data 
was fit to the equation for noncompetitive inhibition (given in Section 2) 
and the best fit is shown as the solid line. For inhibitor-l, PP1 was at 42 
/xU/ml and [32p]histone H4 was 0.3/xM; for inhibitor-2, PP1 was at 160 
/xU/ml and [32 P]histone H4 was 0.3 /xM. 
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Fig. 4. Noncompetitive inhibition kinetics for protein histidine phos- 
phatase activity of PPI. The solid lines show the best fit to the Henderson 
equation for noncompetitive inhibition (the equation is given in Section 2 
and the best fit parameters are listed in Table 2). (A) Inhibitor-l; the 
concentrations shown were 0, 1.3 and 5.8 nM. Data were also obtained at 
0.25 nM but are not shown, for clarity. (B) Okadaic acid; the concentra- 
tions shown were 0, 16 and 50 nM. 
fit parameters for Fig. 5A,B are given in Table 2 and these 
were used to draw the solid lines in Fig. 4 and Fig. 5. For 
Fig. 6 the best fits to noncompetitive inhibition are shown. 
The following inhibition constants were used to draw the 
lines in the figures: K i = 0.2 nM (Fig. 5); K i = 15 nM 
(Fig. 6, PP1); Kii = 0.02 nM, Ka~ = 0.01 nM (Fig. 6, 
PP2A). 
3.  Resu l t s  
Protein histidine phosphatase activity was determined 
using a substrate labeled specifically on histidine [33]. 
Initial rates of reaction were used to confirm agreement 
with the Michaelis-Menten equation, Fig. 1. Table 1 gives 
the best-fit values of K M and Vma x. The Mg 2÷ require- 
ment for PP2C showed a maximum at 4-5 mM and a 
significant reduction in activity at higher [Mg 2÷ ] (Fig. 2). 
Inhibition of protein histidine phosphatase activity of PP1 
by inhibitor-1 and inhibitor-2 was indistinguishable, by 
IC50, from inhibition of the protein serine phosphatase 
activity (Fig. 3). Inhibitor-1 was non-competitive (Fig. 4) 
with K i = 0.7 nM. 
The protein serine phosphatase activity of PP1 and 
PP2A is very specifically inhibited by several natural 
products, including okadaic acid [6] and microcystin [38]. 
Microcystin-LR inhibits the histidine phosphatase activity 
of PP2A with an IC50 of 0.4 nM (Fig. 5). Okadaic acid 
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Fig. 5. Inhibition of protein histidine phosphatase activity of PP2A by 
microcystin-LR. Microcystin concentration is shown on a logarithmic 
scale. The vertical broken line is at 1 nM and the horizontal broken line is 
at 50% inhibition. PP2A was at 100 /zU/ml and [32P]histone H4 was 1 
/xM. 
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Fig. 6. Inhibition of protein histidine phosphatase activity of PPI and 
PP2A by okadaic acid. Okadaic acid concentration is shown on a 
logarithmic scale. The vertical broken line is at 1 nM okadaic acid and 
the horizontal broken line is at 50% inhibition. The data were fitted to the 
equation for noncompetitive inhibition (given in Section 2) and the best 
fits are shown as the solid lines. PP1 was at 42 /xU/ml,  PP2A was at 6.3 
/ zU/ml  and [32P]histone H4 was 0.3 ~M (PP1 curve) or 0.7 ~M (PP2A 
carve). 
distinguishes between PPIL and PP2A, being much more 
potent with PP2A (Fig. 6). As okadaic acid is a tight-bind- 
ing inhibitor, the apparent ICs0 varies with enzyme con- 
centration. A set of equations, given in Section 2, was 
derived from Henderson's equations [37] and used to 
analyse the kinetic data without making the conventional 
assumption of low inhibitor binding relative to inhibitor 
concentration. 
The mechanism of inhibition of PP1 by okadaic acid 
was found to be non-competitive by varying the substrate 
concentration atdifferent okadaic acid concentrations. The 
best fit kinetic constants are given in Table 2. 
Two protein phosphatases not previously tested with a 
substrate containing phosphohistidine were incubated with 
[32 P]H4. The A phage-encoded phosphatase [39] was highly 
active in releasing phosphate from phosphohistidine in
histone H4 under conditions imilar to those used for PP1 
Table 2 
Inhibition of protein histidine phosphatase 
Inhibitor Phosphatase IC50nM K i nM K s /~M [E ] t /g  i 
Inhibitor- 1 PPI 1 0.9 0.5 0.9 
Inhibitor-2 PP 1 3 - - - 
Okadaic acid PP 1 30 32 0.6 0.013 
Okadaic acid PP2A (I.02 - - - 
Microcystin-LR PP2A 1 - - - 
K i and K~ values were determined as described in Section 2 for simple 
non-competitive inhibition using data relating reaction rate to substrate 
concentration at several inhibitor concentrations. The equations used did 
not rely on the assumption of relatively low inhibitor binding since this 
fails in the case of inhibitor-1 [73,74]. 
and PP2A (1 /.,g/ml of A phosphatase contained more 
than 4 mU/ml of protein histidine phosphatase activity 
under the standard assay conditions [33]). In contrast, a 
phosphatase (the product of the human CL100 gene) that 
dephosphorylates MAP kinase [40] was completely inac- 
tive against [32 P]H4. 
4. Discussion 
Protein phosphatases 1 and 2A comprise most of the 
divalent ion-independent protein serine/threonine phos- 
phatase activity in eukaryotic ells [1,41,42]. PP1 and 
PP2A are related but distinct proteins [43-45]. Each has 
more than one isoform [46,47] and several other members 
of this family of protein phosphatases have been isolated 
through DNA sequence homology [48]. The other two 
families of serine/threonine protein phosphatases are diva- 
lent ion-dependent: PP2B requiring Ca2+; and PP2C re- 
quiting Mg 2+. Under physiological conditions these en- 
zymes do not attack phosphotyrosine. The other major 
phosphorylated amino acid that has been found in cells is 
phosphohistidine in which the phosphate is bound to the 
amino acid residue through a phosphoramidate (P-N) bond 
rather than the phosphoester (P-O) bond found in phospho- 
serine and phosphothreonine. Surprisingly, it was recently 
found that PP1, PP2A and PP2C do attack phosphohisti- 
dine [30] although primarily qualitative data was collected 
on this hitherto unknown activity. PP2B, and the protein 
tyrosine phosphatase, PTP-1B, did not attack phosphohisti- 
dine. In this paper, two dual-specificity protein phospha- 
tases have been tested. The list of protein phosphatases 
that work with phosphohistidine in histone H4 now com- 
prises PP1, PP2A, PP2C and the A-encoded protein phos- 
phatase; the list of protein phosphatases that do not work 
with this substrate includes PTP-IB, PP2B and the product 
of the human CL100 gene. The phosphohistidine phos- 
phatase activity of PP1, PP2A and PP2C has now been 
systematically characterized, allowing a careful assessment 
of the significance of the newly discovered activity. 
The protein histidine phosphatase activity of PPI is 
described well by the Michaelis-Menten equation with a 
K M for the [32p]H4 substrate of 0.8 /zM. PPI appears to 
be present in chromatin at high concentration [1,49] and 
histone H4 has been reported to be phosphorylated on 
histidine [14,15]. The histone H4 concentration i  nuclei is 
much higher than 0.8 /zM but the concentration of phos- 
phorylated histone H4 is not known, although overall 
nuclear proteins in Physarum have 5-7% of their phos- 
phate in phosphohistidine (Pesis and Matthews, unpub- 
lished). Thus, the kinetic parameters for PP1 are fully 
consistent with it acting as a protein histidine phosphatase 
in vivo. 
In the cell, PP1 is mostly, if not entirely, complexed 
with other proteins o that it is found predominantly in the 
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particulate fraction of homogenized cells [1]. The PP1 in 
the cytoplasm is complexed with an inhibitor protein, 
inhibitor-2, to form PPII  which does not show 
serine/threonine phosphatase activity [50-53]. Inhibitor-2 
acts as a molecular chaperone to fold PP1 into its active 
conformation [54]. Inhibitor-2 inhibits the protein histidine 
phosphatase activity of PP1 with an IC50 in the nanomolar 
range. Thus, PPII is expected to be inactive towards 
phosphohistidine-containing substrates as it is towards 
phosphoserine or phosphothreonine-containing substrates. 
Cells contain another specific protein inhibitor of PPI, 
inhibitor-1 [55,56], which is closely related to the 
dopamine-regulated neuronal phosphoprotein, DARPP-32 
[57]. Inhibitor-1 inhibits the protein histidine phosphatase 
activity of PP1 with an IC50 in the nanomolar range (Table 
2), comparable with the inhibition of the protein serine 
phosphatase activity. The mechanism of inhibition is non- 
competitive with an inhibition constant, Ki, for [32 P]H4 of 
only 0.9 nM. The low K~ made it necessary to use more 
general equations for analysis of the kinetic data since the 
conventional approximation of low binding relative to 
inhibitor concentration no longer holds. 
The protein histidine phosphatase activity of PP2A is 
described well by the Michaelis-Menten equation with a 
K M for the [32p]H4 substrate of 3/xM. PP2A is also found 
in chromatin [1,49] and thus, like PP1, has the potential to 
dephosphorylate histone H4 in vivo. 
Many studies of protein phosphorylation are carried out 
using specific enzyme inhibitors. For example, genistein is 
used as a tyrosine kinase inhibitor and may have potential 
as an anti-tumour agent [58]. Genistein also inhibits protein 
histidine kinase [59]. In the case of protein phosphatases, a 
number of inhibitors, including okadaic acid, are used to 
infer the involvement of protein serine/threonine phospha- 
tases in cellular events. In fact, okadaic acid is a potent 
tumour promoter with multiple effects on cells [6,60-65]. 
Okadaic acid has potent effects on the protein histidine 
phosphatase activity of PP2A (IC50 = 20 pM) and also 
inhibits the same activity of PP1 (IC50 = 30 nM). Inhibi- 
tion of PP1 is noncompetitive with an inhibition constant, 
Ki, of 32 nM; the inhibition mechanism for PP2A is also 
probably noncompetitive (data not shown). Since the effect 
on the histidine phosphatase activity is essentially indistin- 
guishable from the effect on the serine phosphatase activ- 
ity, the cellular effects of okadaic acid may be due to 
effects on either histidine phosphorylation or 
serine/threonine phosphorylation, or both. This needs to 
be taken into account when interpreting the results of 
experiments with okadaic acid. 
PP2C has a relatively low K M (1.6/xM) for the [32p]H4 
substrate. PP2C requires Mg 2+ for its protein histidine 
phosphatase activity but, unlike the serine phosphatase 
activity, the histidine phosphatase activity is inhibited by 
[Mg 2÷ ] above 5 mM. This may be due to aggregation of 
the substrate rather than an intrinsic property of PP2C. 
Thus, the [Mg 2÷ ] required for apparently half maximal 
activation of the histidine phosphatase activity of PP2C is 
about 1 mM while the corresponding value for the serine 
phosphatase activity is 5 mM [36]. 
Comparison of the K M values for phosphorylase a and 
histone H4 shows that histone H4 has the lower K M in all 
cases suggesting that PP1 and, to a lesser extent, PP2A 
have a higher affinity for the histidine site on histone H4 
than for the serine site on phosphorylase a. The histidine 
site on histone H4 (residue 75) is highly charged and very 
hydrophilic: -Thr-Tyr-Thr-Glu-His-Ala-Lys-Arg-Lys-Thr-. 
Basic proteins and other molecules such as heparin or 
polyamines affect the activity of PPI and PP2A [I]. With 
phosphorylase a, PP1 is inhibited by basic proteins [1]. The 
low K M for phosphorylated histone H4 suggests that the 
active site of PP1 may bind basic molecules trongly. If so, 
this suggestion predicts that the inhibition of PP1 by basic 
proteins and other molecules may be competitive. The K M 
for histone H4 and PP2A is not as low as for PP1, 
suggesting that the active site of PP2A may be less acidic. 
This is supported by the fact that basic proteins inhibit 
PP2A only at high concentrations. At low concentrations, 
basic proteins activate PP2A. The histone H4 concentra- 
tions used in the current study were generally less than 1 
/zM and are thus in the range that would activate PP2A 
[1]. This may account for the higher kca t of PP2A for 
histone H4 than for phosphorylase a. 
Although various criteria may be used to determine the 
substrate preference of an enzyme, the ratio kcat//KM is a 
good way to take into account he effects of both K M and 
Vma x. By this criterion, histidine in histone H4 is preferred 
to serine in phosphorylase a by both PPI and PP2A; PP2C 
uses histone H4 equally with myosin P-light chain. Given 
the wide range of kcat /K  M values for different enzymes, 
all the kcat//KM values are reasonably close and, in rang- 
ing up to 10 or 11 /xM-ls  1, show the phosphatases 
working with high efficiency with either substrate, since a 
diffusion-controlled reaction would have a kcat/K M of 
about 100 to 1000 /xM-ls  -1 [66]. 
In prokaryotes, the two-component system-which in- 
volves histidine phosphorylation-plays a central role in a 
major group of signal transduction mechanisms [67,68] and 
similar roles may occur in eukaryotes [20-22]. The study 
of the enzymes in eukaryotes capable of phosphorylating 
proteins on histidine has produced a novel protein kinase 
that appears to be specific for histidine phosphorylation 
and differs from the two-component system in phospho- 
rylating an exogenous ubstrate [25]. The role of this 
protein histidine phosphorylation i eukaryotes has been 
speculated to involve an anti-proliferation r pro-differenti- 
ation signal [7,69]. We now demonstrate hat three major 
cellular protein serine/threonine phosphatases are as ac- 
tive with phosphohistidine as with phosphoserine. Thus, 
eukaryotic ells have the enzymatic machinery to regulate 
protein phosphorylation  histidine. It remains to identify 
the cellular proteins that are so phosphorylated and to 
determine their roles in eukaryotes. 
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